Advancing AlzeCure

AlzeCure plans to bring its Alzheimer’s programs to the clinic with $22M IPO

Stockholm-based AlzeCure Pharma AB is planning to raise SEK200 million ($22 million) in an IPO on NASDAQ First North Premier to bring both arms of its Alzheimer’s disease portfolio to the clinic.

In a prospectus filed on Nov. 6, the company announced

Read the full 423 word article

User Sign In